Trial
NCT04318145
Study to Evaluate Sex Differences in the Acute Effects of PL-3994 in Heart Failure Subjects
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Palatin Technologies, Inc
Collaborators
—
Condition
Heart Failure With Preserved Ejection Fraction
Intervention
PL-3994 Aqueous Intravenous Solution Dose Ascention
Why stopped
Study cancelled after Part A. Enrollment taking too long.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-12-15